Capacity	Range of estimated annual energy consumption (therms/yr. and gallons/yr.)			
First hour rating	Natural gas therms/yr.		Propane gallons/yr.	
	Low	High	Low	High
30 to 34	(*)	(*)	(*)	(*)
35 to 40	(*)	(*)	(*)	(*)
41 to 47	(*)	(*)	(*)	(*)
48 to 55	(*)	(*)	(*)	(*)
56 to 64	(*)	(*)	(*)	(*)
65 to 74	(*)	(*)	(*)	(*)
75 to 86	(*)	(*)	(*)	(*)
87 to 99	(*)	(*)	(*)	(*)
100 to 114	230	234	252	256
115 to 131	(*)	(*)	(*)	(*)
Over 131	161	238	184	260

*No data submitted.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 98–23150 Filed 8–27–98; 8:45 am]

BILLING CODE 6750–01–M

DELAWARE RIVER BASIN COMMISSION

18 CFR Part 401

Rules of Practice and Procedure

AGENCY: Delaware River Basin Commission.

ACTION: Correcting amendments.

SUMMARY: This document contains corrections to the final regulations which were published in the **Federal Register** on Thursday, December 4, 1997 (62 FR 64154).

DATES: Effective August 28, 1998.

FOR FURTHER INFORMATION CONTACT: Susan M. Weisman, Commission Secretary. Telephone (609) 883–9500 ext. 203.

SUPPLEMENTARY INFORMATION:

List of Subjects in 18 CFR Part 401

Administrative practice and procedure, Environmental impact statements, Freedom of information, Water pollution control, Water resources.

Accordingly, 18 CFR part 401 is corrected by making the following correcting amendments:

PART 401—RULES OF PRACTICE AND PROCEDURE

1. The authority citation for part 401 continues to read as follows:

Authority: Delaware River Basin Compact, 75 Stat. 688.

2. Subpart E heading is revised to read as follows:

Subpart E—Appeals or Objections to Decisions of the Executive Director in Water Quality Cases

3. In § 401.72, the first sentence is revised to read as follows:

§ 401.72 Notice and request for hearing.

The Executive Director shall serve notice of an action or decision by him under the regulations in this chapter by personal service or certified mail, return receipt requested. * * *

4. § 401.74(b)(6) is revised to read as follows:

§ 401.74 Form and contents of report.

* * * * *

(b) * * *

(6) An analysis of all the parameters that may have an effect on the strength of the waste or impinge upon the water quality criteria set forth in the regulations in this chapter, including a determination of the rate of biochemical oxygen demand and the projection of a first-stage carbonaceous oxygen demand;

5. In § 401.106, the address is revised to read as follows:

§ 401.106 FOIA Officer.

* * * * *

FOIA Officer, Delaware River Basin Commission, P.O. Box 7360, West Trenton, NJ 08628–0360.

6. § 401.112(e) is revised to read as follows:

§ 401.112 Exempt information.

* * * * *

(e) Personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy; and

* * * * *

Dated: August 20, 1998.

Susan M. Weisman,

Secretary.

[FR Doc. 98–23048 Filed 8–21–98; 8:45 am]

BILLING CODE 6360–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 74

[Docket No. 95C–0399]

Listing of Color Additives for Coloring Sutures; D&C Violet No. 2; Confirmation of Effective Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; confirmation of effective date.

SUMMARY: The Food and Drug Administration (FDA) is confirming the effective date of May 27, 1998, for the final rule that amended the color additive regulations to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/trimethylene carbonate tripolymer absorbable sutures for general surgery.

DATES: Effective date confirmed: May 27, 1998.

FOR FURTHER INFORMATION CONTACT: Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3089.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 23, 1998 (63 FR 20096), FDA amended the color additive regulations in § 74.3602 *D&C Violet No. 2* (21 CFR 74.3602) to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/

trimethylene carbonate tripolymer absorbable sutures for general surgery.

FDA gave interested persons until May 26, 1998, to file objections or requests for a hearing. The agency received no objections or requests for a hearing on the final rule. Therefore, FDA finds that the effective date of the final rule that published in the **Federal Register** of April 23, 1998, should be confirmed.

List of Subjects in 21 CFR Part 74

Color additives, Cosmetics, Drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 341, 342, 343, 348, 351, 352, 355, 361, 362, 371, 379e) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), notice is given that no objections or requests for a hearing were filed in response to the April 23, 1998, final rule. Accordingly, the amendments issued thereby became effective May 27, 1998.

Dated: August 13, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–23106 Filed 8–27–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Neomycin Sulfate Soluble Powder and Oral Solution

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental abbreviated new animal drug application (ANADA) filed by Phoenix Scientific, Inc. The supplemental ANADA provides for revised withdrawal times for oral solution as a drench and in drinking water for the treatment and control of colibacillosis in cattle (excluding veal calves), swine, sheep, and goats.

EFFECTIVE DATE: August 28, 1998.

FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0209.

SUPPLEMENTARY INFORMATION: Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506–0457, is the sponsor of ANADA 200–118 that provides for the use of neomycin sulfate soluble powder and oral solution as a drench in milk, or in drinking water for the treatment and control of colibacillosis in cattle (excluding veal calves), swine, sheep, and goats. The sponsor filed a supplement that provides for the revised withdrawal periods for the use of the generic product to be identical to that of the pioneer product.

The supplemental ANADA is approved as a generic copy of Pharmacia & Upjohn's NADA 011–315 Neomix®. Supplemental ANADA 200–118 is approved as of July 14, 1998, and the regulations are amended in 21 CFR 520.1485 to reflect the approval for the neomycin sulfate solution. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 520.1485 [Amended]

3. Section 520.1485 *Neomycin sulfate oral solution* is amended in paragraph (d)(3) by removing ''For sponsor 059130: 30 days for cattle and goats, and 20 days for swine and sheep; for sponsors 000009 and 050604:''.

Dated: August 17, 1998.

Andrew J. Beaulieu,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 98–23108 Filed 8–27–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Pyrantel Pamoate Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Phoenix Scientific, Inc. The ANADA provides for use of pyrantel pamoate suspension for removal of large roundworms and hookworms and to prevent reinfections of *Toxocara canis* in puppies and adult dogs and in lactating bitches after whelping.

EFFECTIVE DATE: August 28, 1998.

FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0209.

SUPPLEMENTARY INFORMATION: Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506–0457 has filed ANADA 200–248 that provides for oral use of pyrantel pamoate suspension for removal of large roundworms (*T. canis* and *Toxascaris leonina*) and hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*) and to prevent reinfections of *T. canis* in puppies and adult dogs and in lactating bitches after whelping.

The ANADA is approved as a generic copy of Pfizer, Inc.'s NADA 100–237 Nemex™ and Nemex-2™ (pyrantel pamoate) suspension. ANADA 200–248 is approved as of July 16, 1998, and the regulations are amended in 21 CFR 520.2043(b)(2) to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug